WallStreetZenWallStreetZen

NASDAQ: KTRA
Kintara Therapeutics Inc Stock

$0.10+0.01 (+11.11%)
Updated Mar 28, 2024
KTRA Price
$0.10
Fair Value Price
N/A
Market Cap
$4.06M
52 Week Low
$0.08
52 Week High
$5.98
P/E
-0.02x
P/B
-24.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-12.49
Operating Cash Flow
-$7M
Beta
0.71
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KTRA Overview

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KTRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KTRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KTRA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
KTRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more KTRA due diligence checks available for Premium users.

Be the first to know about important KTRA news, forecast changes, insider trades & much more!

KTRA News

Valuation

KTRA fair value

Fair Value of KTRA stock based on Discounted Cash Flow (DCF)
Price
$0.10
Fair Value
$0.95
Undervalued by
89.45%
KTRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KTRA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.02x
Industry
14.26x
Market
44.51x

KTRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-24.76x
Industry
6.21x

KTRA's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.0M
Profit Margin
0%
KTRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$1.9M
Liabilities
$2.0M
Debt to equity
-12.49
KTRA's short-term liabilities ($1.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KTRA's short-term assets ($1.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KTRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KTRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.1M
Investing
-$20.0k
Financing
$2.6M
KTRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KTRA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KTRA$4.06M+16.85%-0.02x-24.76x
MYMD$4.06M+1.70%-0.44x0.26x
FNCH$4.17M-10.16%-0.06x0.18x
SCPX$4.23M-1.22%-0.08x0.12x
LIPO$4.28M-4.86%-0.89x1.36x

Kintara Therapeutics Stock FAQ

What is Kintara Therapeutics's quote symbol?

(NASDAQ: KTRA) Kintara Therapeutics trades on the NASDAQ under the ticker symbol KTRA. Kintara Therapeutics stock quotes can also be displayed as NASDAQ: KTRA.

If you're new to stock investing, here's how to buy Kintara Therapeutics stock.

What is the 52 week high and low for Kintara Therapeutics (NASDAQ: KTRA)?

(NASDAQ: KTRA) Kintara Therapeutics's 52-week high was $5.98, and its 52-week low was $0.08. It is currently -98.26% from its 52-week high and 28.4% from its 52-week low.

How much is Kintara Therapeutics stock worth today?

(NASDAQ: KTRA) Kintara Therapeutics currently has 39,037,899 outstanding shares. With Kintara Therapeutics stock trading at $0.10 per share, the total value of Kintara Therapeutics stock (market capitalization) is $4.06M.

Kintara Therapeutics stock was originally listed at a price of $3,400.00 in Feb 22, 2013. If you had invested in Kintara Therapeutics stock at $3,400.00, your return over the last 11 years would have been -100%, for an annualized return of -61.13% (not including any dividends or dividend reinvestments).

How much is Kintara Therapeutics's stock price per share?

(NASDAQ: KTRA) Kintara Therapeutics stock price per share is $0.10 today (as of Mar 28, 2024).

What is Kintara Therapeutics's Market Cap?

(NASDAQ: KTRA) Kintara Therapeutics's market cap is $4.06M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kintara Therapeutics's market cap is calculated by multiplying KTRA's current stock price of $0.10 by KTRA's total outstanding shares of 39,037,899.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.